ArticlePoultry science2026
Recombinant human adenovirus type 5-vectored vaccine expressing avian reovirus σC protein protects against prevalent genotype I avian reovirus in chickens.
Article in Poultry science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Avian reovirus (ARV) is a globally important poultry pathogen causing substantial economic losses due to viral arthritis, enteritis and immunosuppression. Traditional vaccines based on the S1133 strain are less effective against circulating ARV variants due to genetic divergence. The σC protein is the primary antigen inducing neutralizing antibodies against ARV, making it a key target for vaccine development. Here, we constructed a recombinant human adenovirus type 5 (rHAdV5) vector vaccine expressing the σC protein of a prevalent Chinese ARV field strain (SDAU-1) and evaluated its safety, immunogenicity and protective efficacy in specific-pathogen-free (SPF) chickens. The recombinant vaccine rHAdV5-ARV-σC stably expressed the ∼36 kDa σC protein and maintained genetic stability over 13 serial passages. Immunization of 1-day-old SPF chickens with 10⁹ PFU rHAdV5-ARV-σC elicited robust ARV-specific IgG antibodies (peak titer 1:3500 at 7 days post-immunization) and significantly elevated serum IFN-γ and IL-4 levels (P < 0.05), indicating activation of both humoral and cellular immune responses. Following challenge with the SDAU-1 strain at 7 days of age, the vaccine provided an 86% (26/30) protection rate, markedly reduced viral shedding and tissue viral loads, and alleviated pathological lesions and immune organ damage compared to unvaccinated controls. These results demonstrate that rHAdV5-ARV-σC is a safe, immunogenic, and effective vaccine candidate against prevalent ARV strains, with high potential for controlling ARV infections in commercial poultry production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.